MXPA04011427A - Formas seudopolimorficas de un inhibidor de proteasa del virus de inmunodeficiencia adquirida. - Google Patents
Formas seudopolimorficas de un inhibidor de proteasa del virus de inmunodeficiencia adquirida.Info
- Publication number
- MXPA04011427A MXPA04011427A MXPA04011427A MXPA04011427A MXPA04011427A MX PA04011427 A MXPA04011427 A MX PA04011427A MX PA04011427 A MXPA04011427 A MX PA04011427A MX PA04011427 A MXPA04011427 A MX PA04011427A MX PA04011427 A MXPA04011427 A MX PA04011427A
- Authority
- MX
- Mexico
- Prior art keywords
- protease inhibitor
- hiv protease
- pseudopolymorphic forms
- forms
- pseudopolymorphic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen nuevas formas seudopolimorficas de (3R, 3aS, 6aR)- hexahidrofuro [2, 3-b] furan-3- il (1S, 2R)3- [[(4- aminofenil) sulfonil] (isobutil) amino]-l -bencil-1- hidroxipropilcarbamato y procedimientos para producir las mismas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02076929 | 2002-05-16 | ||
PCT/EP2003/050176 WO2003106461A2 (en) | 2002-05-16 | 2003-05-16 | Pseudopolymorphic forms of a hiv protease inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04011427A true MXPA04011427A (es) | 2005-02-17 |
Family
ID=29724454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04011427A MXPA04011427A (es) | 2002-05-16 | 2003-05-16 | Formas seudopolimorficas de un inhibidor de proteasa del virus de inmunodeficiencia adquirida. |
Country Status (26)
Country | Link |
---|---|
US (8) | US7700645B2 (es) |
EP (4) | EP1567529B2 (es) |
JP (1) | JP4864320B2 (es) |
KR (2) | KR20100119906A (es) |
CN (1) | CN100475819C (es) |
AP (1) | AP2052A (es) |
AU (2) | AU2003271740B2 (es) |
BR (1) | BRPI0311176B8 (es) |
CA (1) | CA2485834C (es) |
CY (3) | CY1115665T1 (es) |
DK (3) | DK2767539T3 (es) |
EA (1) | EA007120B8 (es) |
ES (4) | ES2498370T5 (es) |
HK (1) | HK1081969A1 (es) |
HR (1) | HRP20041061B1 (es) |
HU (1) | HUE034389T2 (es) |
IL (1) | IL165140A0 (es) |
LT (1) | LT2767539T (es) |
MX (1) | MXPA04011427A (es) |
NO (1) | NO331477B1 (es) |
NZ (1) | NZ536497A (es) |
PL (1) | PL215151B1 (es) |
PT (3) | PT2767539T (es) |
SI (3) | SI2314591T2 (es) |
WO (1) | WO2003106461A2 (es) |
ZA (1) | ZA200410154B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2336160C (en) | 1998-06-23 | 2015-02-17 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of compounds for treating hiv |
AU2003271740B2 (en) | 2002-05-16 | 2010-05-13 | Janssen R&D Ireland | Pseudopolymorphic forms of a HIV protease inhibitor |
HRP20020614A2 (en) * | 2002-07-22 | 2004-06-30 | PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. | Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a |
RS51073B (sr) | 2003-12-23 | 2010-10-31 | Tibotec Pharmaceuticals Ltd. | Proces za pripremanje (3r,3as,6ar)-heksahidrofuro│2,3-b│ furan-3-il (1s,2r)-3-││(4-aminofenil) sulfonil│(izobutil) amino │-1-benzil-2-hidroksipropilkarbamata |
MX2007010378A (es) | 2005-02-25 | 2007-09-25 | Tibotec Pharm Ltd | Sintesis del precursor inhibidor de la proteasa. |
PL2089371T3 (pl) * | 2006-11-09 | 2011-06-30 | Janssen Sciences Ireland Uc | Sposoby wytwarzania heksahydrofuro[2,3-b]furan-3-olu |
AR073248A1 (es) | 2008-09-01 | 2010-10-20 | Tibotec Pharm Ltd | Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso. |
PL2381786T3 (pl) | 2009-01-29 | 2015-06-30 | Mapi Pharma Ltd | Dimetylosulfotlenkowy solwat darunawiru |
US8921415B2 (en) | 2009-01-29 | 2014-12-30 | Mapi Pharma Ltd. | Polymorphs of darunavir |
WO2011048604A2 (en) * | 2009-09-17 | 2011-04-28 | Matrix Laboratories Limited | An improved process for the preparation of darunavir |
BR112012009956A2 (pt) | 2009-10-30 | 2015-09-29 | Lupin Ltd | um novo processo para a preparação de darunavir e etanolato darunavir de tamanho de partícula. |
CN102686594A (zh) * | 2009-12-16 | 2012-09-19 | 熙德隆研究基金会 | 地瑞那韦的多晶型物 |
WO2011083287A2 (en) * | 2010-01-05 | 2011-07-14 | Cipla Limited | Darunavir polymorph and process for preparation thereof |
WO2011092687A1 (en) | 2010-01-28 | 2011-08-04 | Mapi Pharma Hk Limited | Process for the preparation of darunavir and darunavir intermediates |
US8853430B2 (en) * | 2010-05-20 | 2014-10-07 | Hetero Research Foundation | Crystalline hydrochloride salt of darunavir |
WO2012107889A1 (en) | 2011-02-10 | 2012-08-16 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous darunavir |
DK2729130T3 (en) | 2011-07-07 | 2017-12-11 | Janssen Sciences Ireland Uc | Darunavir-COMBINATION FORMULATIONS |
WO2013114382A1 (en) | 2011-12-05 | 2013-08-08 | Mylan Laboratories Ltd | Crystalline darunavir |
EP2804869B1 (en) * | 2012-01-18 | 2019-06-12 | Aurobindo Pharma Limited | Novel solvates of darunavir |
CN103509031B (zh) * | 2012-06-20 | 2016-04-27 | 上海迪赛诺药业有限公司 | 制备达芦那韦无定形物的方法 |
ES2969589T3 (es) * | 2012-07-24 | 2024-05-21 | Laurus Labs Ltd | Solvato de Propionato de Darunavir |
WO2014068265A1 (en) | 2012-10-29 | 2014-05-08 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
US9346820B2 (en) * | 2013-09-11 | 2016-05-24 | Purdue Research Foundation | HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands |
WO2016092525A1 (en) * | 2014-12-12 | 2016-06-16 | Lupin Limited | Darunavir n-propanol solvate and process for preparation thereof |
WO2016092527A1 (en) * | 2014-12-12 | 2016-06-16 | Sun Pharmaceutical Industries Limited | A process for the preparation of dolutegravir |
AU2016233113B2 (en) | 2015-03-19 | 2020-05-07 | Mycovia Pharmaceuticals, Inc. | Antifungal compounds and processes for making |
BR112019002132A2 (pt) | 2016-08-08 | 2019-05-14 | Hetero Labs Limited | composições anti-retrovirais |
BR112019002120A2 (pt) | 2016-08-08 | 2019-05-14 | Hetero Labs Limited | composição anti-retroviral de várias classes |
EP3532478B1 (en) | 2016-10-27 | 2021-05-26 | Gilead Sciences, Inc. | Crystalline form of darunavir free base |
CN108727401A (zh) * | 2017-04-20 | 2018-11-02 | 盐城迪赛诺制药有限公司 | 达鲁那韦新晶型及其制备方法和应用 |
CN109053753A (zh) * | 2018-08-05 | 2018-12-21 | 浙江大学 | 一种制备达卢那韦二水合物晶型的方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
JPH05230044A (ja) | 1992-02-21 | 1993-09-07 | Hoechst Japan Ltd | ピレタニドの新規な結晶多形 |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
ATE174587T1 (de) | 1993-08-24 | 1999-01-15 | Searle & Co | Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen |
PT812320E (pt) * | 1995-02-22 | 2000-12-29 | Aventis Pharma Ltd | Firetanido amorfo piretanido polimorfo processo para a sua preparacao e sua utilizacao |
ZA984514B (en) * | 1997-05-29 | 1998-11-30 | Merck & Co Inc | Hiv protease inhibitor |
GB9712253D0 (en) | 1997-06-13 | 1997-08-13 | Glaxo Group Ltd | Antiviral compound |
US6287693B1 (en) * | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
GB9805898D0 (en) * | 1998-03-20 | 1998-05-13 | Glaxo Group Ltd | Process for the sythesis of hiv protease inhibitors |
GB9807354D0 (en) | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
AU4828199A (en) * | 1998-06-23 | 2000-01-10 | Board Of Trustees Of The University Of Illinois, The | Multi-drug resistant retroviral protease inhibitors and associated methods |
CA2336160C (en) * | 1998-06-23 | 2015-02-17 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of compounds for treating hiv |
US6225317B1 (en) | 1998-11-19 | 2001-05-01 | Dupont Pharmaceuticals Company | Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone |
SI1159278T1 (sl) | 1999-02-12 | 2006-06-30 | Vertex Pharma | Inhibitorji aspartil proteaze |
AU2003271740B2 (en) | 2002-05-16 | 2010-05-13 | Janssen R&D Ireland | Pseudopolymorphic forms of a HIV protease inhibitor |
WO2011083287A2 (en) * | 2010-01-05 | 2011-07-14 | Cipla Limited | Darunavir polymorph and process for preparation thereof |
-
2003
- 2003-05-16 AU AU2003271740A patent/AU2003271740B2/en not_active Revoked
- 2003-05-16 KR KR1020107024106A patent/KR20100119906A/ko not_active Application Discontinuation
- 2003-05-16 SI SI200332383T patent/SI2314591T2/sl unknown
- 2003-05-16 ES ES03753571T patent/ES2498370T5/es not_active Expired - Lifetime
- 2003-05-16 SI SI200332545T patent/SI2767539T1/sl unknown
- 2003-05-16 WO PCT/EP2003/050176 patent/WO2003106461A2/en active Application Filing
- 2003-05-16 EP EP03753571.3A patent/EP1567529B2/en not_active Expired - Lifetime
- 2003-05-16 CN CNB038164590A patent/CN100475819C/zh not_active Expired - Lifetime
- 2003-05-16 PL PL374321A patent/PL215151B1/pl unknown
- 2003-05-16 DK DK14168686.5T patent/DK2767539T3/en active
- 2003-05-16 EP EP16158480.0A patent/EP3045460B1/en not_active Expired - Lifetime
- 2003-05-16 MX MXPA04011427A patent/MXPA04011427A/es active IP Right Grant
- 2003-05-16 LT LTEP14168686.5T patent/LT2767539T/lt unknown
- 2003-05-16 JP JP2004513292A patent/JP4864320B2/ja not_active Expired - Lifetime
- 2003-05-16 KR KR1020047018426A patent/KR101128370B1/ko active IP Right Grant
- 2003-05-16 PT PT141686865T patent/PT2767539T/pt unknown
- 2003-05-16 ES ES10180831T patent/ES2503551T5/es not_active Expired - Lifetime
- 2003-05-16 AP AP2004003191A patent/AP2052A/xx active
- 2003-05-16 EA EA200401503A patent/EA007120B8/ru unknown
- 2003-05-16 EP EP10180831.9A patent/EP2314591B2/en not_active Expired - Lifetime
- 2003-05-16 HU HUE14168686A patent/HUE034389T2/en unknown
- 2003-05-16 DK DK03753571.3T patent/DK1567529T4/da active
- 2003-05-16 DK DK10180831.9T patent/DK2314591T4/da active
- 2003-05-16 BR BRPI0311176A patent/BRPI0311176B8/pt active IP Right Grant
- 2003-05-16 SI SI200332389T patent/SI1567529T2/sl unknown
- 2003-05-16 EP EP14168686.5A patent/EP2767539B1/en not_active Expired - Lifetime
- 2003-05-16 ES ES16158480T patent/ES2728735T3/es not_active Expired - Lifetime
- 2003-05-16 US US10/514,352 patent/US7700645B2/en active Active
- 2003-05-16 PT PT37535713T patent/PT1567529E/pt unknown
- 2003-05-16 PT PT101808319T patent/PT2314591E/pt unknown
- 2003-05-16 CA CA002485834A patent/CA2485834C/en not_active Expired - Lifetime
- 2003-05-16 NZ NZ536497A patent/NZ536497A/en not_active IP Right Cessation
- 2003-05-16 ES ES14168686.5T patent/ES2638412T3/es not_active Expired - Lifetime
-
2004
- 2004-11-10 IL IL16514004A patent/IL165140A0/xx unknown
- 2004-11-12 HR HRP20041061AA patent/HRP20041061B1/hr not_active IP Right Cessation
- 2004-12-10 NO NO20045409A patent/NO331477B1/no not_active IP Right Cessation
- 2004-12-15 ZA ZA2004/10154A patent/ZA200410154B/en unknown
-
2006
- 2006-02-23 HK HK06102443.3A patent/HK1081969A1/xx not_active IP Right Cessation
-
2009
- 2009-08-06 US US12/536,807 patent/US8518987B2/en not_active Expired - Lifetime
-
2012
- 2012-07-03 AU AU2012205289A patent/AU2012205289A1/en active Pending
-
2013
- 2013-07-11 US US13/939,494 patent/US20130303790A1/en not_active Abandoned
-
2014
- 2014-02-19 US US14/183,712 patent/US20140171499A1/en not_active Abandoned
- 2014-09-17 CY CY20141100755T patent/CY1115665T1/el unknown
- 2014-09-17 CY CY20141100756T patent/CY1117928T1/el unknown
-
2015
- 2015-08-04 US US14/817,827 patent/US20150336980A1/en not_active Abandoned
-
2017
- 2017-05-22 US US15/600,932 patent/US10000504B2/en not_active Expired - Lifetime
- 2017-08-23 CY CY20171100896T patent/CY1119311T1/el unknown
-
2018
- 2018-05-16 US US15/980,993 patent/US10858369B2/en not_active Expired - Lifetime
-
2020
- 2020-10-30 US US17/085,096 patent/US20210179631A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04011427A (es) | Formas seudopolimorficas de un inhibidor de proteasa del virus de inmunodeficiencia adquirida. | |
IL174960A0 (en) | Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate | |
ME01059B (me) | Proces za pripremanje (3r,3as,6ar)-heksahidrofuro [2,3-b] furan-3-il (1s,2r)-3-[[(4-aminofenil) sulfonil] (izobutil) amino]-1-benzil-2- hidroksipropilkarbamata | |
NO20064977L (no) | Fremgangsmater for fremstilling av (3R,3aS,6aR)-heksahydro-furo[2,3-b]furan-3-ol | |
RS51675B (en) | METHODS FOR THE PREPARATION OF HEXAHIDROFURO [2,3-B] FURAN-3-OLA | |
EP1222192B8 (en) | Hexahydrofuro¬2,3-b furan-3-yl-n- 3-¬(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino -1-benzyl-2-hydroxypropyl carbamate as retroviral protease inhibitor | |
AU2003287038A1 (en) | METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO (2, 3-b) FURAN AND RELATED COMPOUNDS | |
HRP20040320B1 (hr) | POSTUPAK ZA PRIPRAVU HEKSAHIDRO-FURO[2,3-b]FURAN-3-OLA | |
WO2005039544A8 (ja) | リン酸カルシウムセラミックス多孔体及びその製造方法 | |
AU2003219662A1 (en) | 4-OXO-4, 7-DIHYDROFURO(2,3-b)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | |
MXPA05006089A (es) | Respiradero anular de moldes para superficie de rodadura de neumaticos. | |
AU2003265383A1 (en) | 4-OXO-4,7-DIHYDROTHIENO(2,3-b)PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | |
WO2005000249A3 (en) | Preparation of chemical compounds | |
YU62502A (sh) | Postupak za jednostavnu proizvodnju (3-hlor-4-fluor-fenil)-7-(3-morfolin-4-il-propoksi)-6-nitro-hinazolin-4-il)-amina odnosno (3-hlor-4-fluor-fenil)-7-(3-morfolin-4-il- propoksi)-6-amino-hinazolin-4-il)-amina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |